10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Inhaled insulin for controlling blood glucose in patients with diabetes

      review-article

      Read this article at

      ScienceOpenPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Diabetes mellitus is a significant worldwide health problem, with the incidence of type 2 diabetes increasing at alarming rates. Insulin resistance and dysregulated blood glucose control are established risk factors for microvascular complications and cardiovascular disease. Despite the recognition of diabetes as a major health issue and the availability of a growing number of medications designed to counteract its detrimental effects, real and perceived barriers remain that prevent patients from achieving optimal blood glucose control. The development and utilization of inhaled insulin as a novel insulin delivery system may positively influence patient treatment adherence and optimal glycemic control, potentially leading to a reduction in cardiovascular complications in patients with diabetes.

          Related collections

          Most cited references91

          • Record: found
          • Abstract: found
          • Article: not found

          Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

          The goal of this study was to estimate the prevalence of diabetes and the number of people of all ages with diabetes for years 2000 and 2030. Data on diabetes prevalence by age and sex from a limited number of countries were extrapolated to all 191 World Health Organization member states and applied to United Nations' population estimates for 2000 and 2030. Urban and rural populations were considered separately for developing countries. The prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030. The prevalence of diabetes is higher in men than women, but there are more women with diabetes than men. The urban population in developing countries is projected to double between 2000 and 2030. The most important demographic change to diabetes prevalence across the world appears to be the increase in the proportion of people >65 years of age. These findings indicate that the "diabetes epidemic" will continue even if levels of obesity remain constant. Given the increasing prevalence of obesity, it is likely that these figures provide an underestimate of future diabetes prevalence.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

            To compare the abilities and associated hypoglycemia risks of insulin glargine and human NPH insulin added to oral therapy of type 2 diabetes to achieve 7% HbA(1c). In a randomized, open-label, parallel, 24-week multicenter trial, 756 overweight men and women with inadequate glycemic control (HbA(1c) >7.5%) on one or two oral agents continued prestudy oral agents and received bedtime glargine or NPH once daily, titrated using a simple algorithm seeking a target fasting plasma glucose (FPG)
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Standards of medical care in diabetes--2007.

                Bookmark

                Author and article information

                Journal
                Vasc Health Risk Manag
                Vascular Health and Risk Management
                Vascular Health and Risk Management
                Dove Medical Press
                1176-6344
                1178-2048
                December 2007
                : 3
                : 6
                : 947-958
                Affiliations
                [1 ]Alkermes, Inc Cambridge, MA, USA
                [2 ]i3 Statprobe, Ann Arbor, MI Indianapolis, IN, USA
                [3 ]Eli Lilly and Company Indianapolis, IN, USA
                Author notes
                Correspondence: Douglas B Muchmore Eli Lilly and Company, DC 6034, Indianapolis, IN 46285, USA Tel +1 317 277 7332 +1 317 529 7537 (mobile) Fax +1 858 459 4997 Email dmuch@ 123456lilly.com
                Article
                2350138
                18200813
                870656be-489a-44ca-9b84-623bd35d35ee
                © 2007 Dove Medical Press Limited. All rights reserved
                History
                Categories
                Review

                Cardiovascular Medicine
                cardiovascular disease,inhaled insulin,diabetes,blood glucose
                Cardiovascular Medicine
                cardiovascular disease, inhaled insulin, diabetes, blood glucose

                Comments

                Comment on this article